{"id":"bms-986368","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BMS-986368 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby unleashing an immune response against cancer cells. This mechanism is thought to be effective in various types of cancer.","oneSentence":"BMS-986368 is an anti-PD-1 monoclonal antibody.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:25.276Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT06782490","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-06-05","conditions":"Multiple Sclerosis Spasticity","enrollment":200},{"nctId":"NCT06808984","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-06-09","conditions":"Agitation, Alzheimer Disease","enrollment":120},{"nctId":"NCT06411730","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity","status":"COMPLETED","sponsor":"Celgene","startDate":"2024-05-31","conditions":"Healthy Participants","enrollment":56},{"nctId":"NCT06170723","phase":"PHASE1","title":"A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants","status":"COMPLETED","sponsor":"Celgene","startDate":"2024-03-18","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT06227975","phase":"PHASE1","title":"A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants","status":"COMPLETED","sponsor":"Celgene","startDate":"2024-02-02","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT05099822","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants","status":"TERMINATED","sponsor":"Celgene","startDate":"2020-03-13","conditions":"Healthy Volunteers","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CC-97489"],"phase":"phase_2","status":"active","brandName":"BMS-986368","genericName":"BMS-986368","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986368 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}